FDA Gets Mylan Suit Over Generic Lipitor Tossed

Law360, New York (May 2, 2011, 9:03 PM EDT) -- A federal judge in Washington on Monday tossed Mylan Pharmaceuticals Inc.'s suit to compel the U.S. Food and Drug Administration to weigh in on Ranbaxy Laboratories Ltd.'s exclusivity provision for marketing a generic version of Lipitor.

Mylan, which filed its own application with the FDA to market a Lipitor generic known as atorvastatin, has no standing to push the agency to act on a competitor's application, U.S. District Judge James E. Boasberg said in his opinion.

The FDA's decision could be lucrative to the company that...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

MYLAN PHARMACEUTICALS INC. et al v. UNITED STATES FOOD AND DRUG ADMINISTRATION


Case Number

1:11-cv-00566

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

James E. Boasberg

Date Filed

March 18, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.